Chordal Systolic Anterior Motion: Clinical Significance
Chordal systolic anterior motion (SAM) on echocardiography indicates anterior displacement of the mitral valve chordae tendineae toward the left ventricular outflow tract (LVOT) during systole, which can occur with or without hypertrophic cardiomyopathy (HCM) and may cause LVOT obstruction and mitral regurgitation.
Key Distinction: Chordal vs. Leaflet SAM
Chordal SAM specifically involves early systolic anterior angular motion ("buckling") of mitral chordal structures rather than movement of the anterior mitral leaflet body itself 1. This is a critical distinction because:
- Chordal SAM is often benign and transient, particularly when seen post-operatively after mitral valve procedures 2
- Leaflet SAM is the classic finding in obstructive HCM and carries more hemodynamic significance 3
Clinical Context and Associations
In HCM Patients
When chordal SAM occurs in HCM, it represents part of the obstructive mechanism 3, 4. The 2024 AHA/ACC HCM guidelines emphasize that SAM related to elongated anterior mitral valve leaflets and papillary muscle abnormalities may result in:
- Leaflet separation or poor coaptation
- Posteriorly directed mitral regurgitation in late systole
- Dynamic LVOT obstruction 3
In Non-HCM Patients
Chordal SAM without HCM has a prevalence of approximately 0.3% in the general population 5 and 3.9% in clinical echocardiographic studies 6. These patients typically demonstrate:
- Older age (mean 65.7 years vs. 56.9 years in HCM patients)
- Sigmoid septum (75% prevalence)
- Lower LVOT gradients (mean 27 mmHg vs. 43 mmHg in HCM) 5
Associated Conditions
Chordal SAM occurs in several clinical scenarios:
- Isolated finding (33% of non-HCM cases) 6
- Mitral valve prolapse (32% of non-HCM cases) - these patients show hyperdynamic LV function with higher ejection fractions (75% vs. 72%) and greater mitral valve excursion 1, 6
- Post-mitral valve surgery - typically transient and benign, though late presentations (>2 years post-op) can occur 2, 7
- Aortic insufficiency and concentric LV hypertrophy 6
- Hypertension and hyperdynamic states 8
Hemodynamic Significance
The clinical impact depends on whether LVOT obstruction develops:
- Valvular SAM produces higher LVOT gradients (mean 39 mmHg), more dyspnea, and more significant mitral regurgitation than chordal SAM (mean 6 mmHg) 5
- Approximately 29% of non-HCM patients with chordal SAM have LVOT gradients >30 mmHg, requiring clinical attention 5
- The tenting area correlates significantly with mitral regurgitation severity 9
Critical Diagnostic Pitfall
Chordal SAM can mimic acute coronary syndrome, presenting with chest pain, dyspnea, and even ST-elevation on ECG 8. This misdiagnosis is dangerous because:
- Standard heart failure therapies (diuretics, vasodilators) can worsen LVOT obstruction and cause hemodynamic collapse
- Beta-blockers are the appropriate treatment, not antiplatelet therapy or revascularization 8
Management Approach
When chordal SAM is identified:
Determine if LVOT obstruction is present - measure resting and provocable gradients (Valsalva, standing) per 2024 guidelines 3, 4
Assess mitral regurgitation severity - evaluate tenting area and regurgitant jet characteristics 9
Rule out HCM - evaluate for asymmetric septal hypertrophy, maximal wall thickness >15mm 3
If obstructive (gradient ≥50 mmHg with symptoms):
- Initiate beta-blocker therapy as first-line treatment 8
- Avoid vasodilators, diuretics, and positive inotropes that worsen obstruction
- Consider disopyramide if beta-blockers insufficient (in HCM context)
If non-obstructive or isolated finding:
- Clinical observation with serial echocardiography
- Address underlying conditions (hypertension, volume status)
Post-surgical cases: Typically resolve spontaneously within 3 months; surgical revision only if persistent with significant obstruction 2, 7
The 2024 HCM guidelines recommend repeat TTE within 3-6 months after any septal reduction therapy to evaluate procedural results and residual SAM 4.